Physician profile

Michael Amin Haft

San Diego, CA

NPI 1922700731

$1,020.30

in general payments reported to CMS, 2019-2025

7 companies · $941 in 2025

The $941 reported for 2025 was more than what 87% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,020.30

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $233.66 2025 Otezla
Ucb, INC. $190.01 2025 Bimzelx
Abbvie INC. $179.82 2025
Galderma Laboratories, L.P. $143.57 2025 Nemluvio
Boehringer Ingelheim Pharmaceuticals, INC. $110.81 2025 Spevigo
Lilly USA, LLC $83.23 2025 Taltz, Ebglyss
Novartis Pharmaceuticals Corporation $79.20 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Amin Haft

$1,020.30

in general payments reported 2019-2025

Years
2024-2025
Top company
Amgen INC.
Context
The $941 reported for 2025 was more than what 87% of providers received nationally.

https://glasscript.com/doctor/11641282/michael-amin-haft

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.